BiotechFeaturedPharmaResearch

NanoViricides: Grab This Biopharma Player While Inexpensive

Human Clinical Trials Could Create Opportunity For Investors

Investment timing is among the most important ideas associated to the world of stock market investing. While its software is essential for investments throughout any and each sector, one specific business the place it’s most related is the biotech business. Often, we see biotech firms with minimal  revenues which can be on the verge of clearing a specific part of trials for a high-potential drug and as soon as the part is cleared, their stock worth zooms as their market capitalization will increase exponentially. Investors getting into the stock earlier than the clearance of the part find yourself with phenomenal returns. One such biopharmaceutical participant that’s on the cusp of getting into human trials for its extremely promising drug candidate is NanoViricides (NYSE-American:NNVC).

About The Company

NanoViricides, Inc. is a Connecticut-based biopharma firm on the improvement stage, with proprietary analysis centered on viral illnesses. Founded in 2005, the corporate has developed its personal standout nanomedicine know-how known as a nanoviricide i.e. a medical agent designed to compel a virus into attaching to an antiviral nanomachine in an effort to neutralize and destroy the identical and stop it from attaching itself to different cells within the physique. The firm has its personal, state-of-the-art cGMP manufacturing facility and its analysis is targeted on all kinds of viral illnesses similar to shingles, herpes, seasonal and potentially-epidemic influenzas and chook flu, HIV/AIDS, chilly sores, viral eye illnesses, and dengue viruses.

IND Application For Its Core Drug Before Heading Towards Human Trials

NanoViricides’ analysis is targeted on three key HerpeCide™ drug improvement applications: dermal topical remedies for Herpes Simplex Virus Type 1 (HSV-1), Herpes Simplex Virus Type 2 (HSV-2) and Varicella Zoster Virus (VZV) which causes chickenpox and shingles. Its core drug candidate is NV-HHV-101, a pores and skin cream for topical remedy of shingles rash brought on by VZV. Most not too long ago, the drug was within the information for its GLP research carried out on minipigs and now, the corporate is advancing it by means of the Safety Pharmacology research involving the central nervous system (CNS), respiratory, and cardiovascular techniques. The impression of the Company’s pores and skin cream on these techniques is required to help its investigational new drug (“IND”) software for the NV-HHV-101 and transfer it into human scientific trials. The drug has already efficiently accomplished the non-GLP portion of the Safety/Pharmacology research. The administration has a powerful perception that for the reason that drug candidate is meant to be administered as a topical formulation to the pores and skin in people, it’s not anticipated to end in bodily systemic publicity which is why it should have no adversarial impact on the CNS, the cardiovascular system, and even the respiratory system. Management’s perception relies on the non-GLP research and likewise preliminary security/toxicology research that have been carried out earlier. Assuming that these research are profitable, the IND bundle of NanoViricides will subsequently be transformed into the “electronic Common Technical Document” (“eCTD) format and submitted to the US FDA.

High Probability of Success In Human Trials

Few pharma and biotech firms can boast of a excessive chance of success on the stage of human trials like NanoViricides and there’s a sturdy rationale for this perception. Over the years, the administration has invested a whole lot of effort in its analysis and has had its justifiable share of failures from which they’ve realized effectively. After incorporating these developments, they’ve proceeded to check its core drug candidate in a human skin-based mannequin of VZV an infection on an ex-vivo foundation, which is utilizing human pores and skin patches cultured in petri dishes and never on reside human beings. These checks have been carried out by viral illness skilled, Professor Moffat on the Upstate Medical Center, SUNY in Syracuse, New York and have been extremely profitable, implying a considerably decrease danger of failure throughout the course of the human trials that shall be undertaken after the IND software.

A Staggering Market With Minimal Competition

As of right this moment, there are between 500,000 to 1 million circumstances of shingles annually within the U.S. alone. The most notable medication energetic on this area are the vaccines meant for the prevention of this virus which embody the Shingrix® vaccine. However, there is no such thing as a topical cream that exists within the market to remedy shingles which signifies that NanoViricides’ NV-HHV-101 might have  a digital monopoly inside this area. The market measurement for this one-of-a-kind drug is estimated at a couple of billion {dollars} after considering the usage of the competing vaccines. Interestingly, that is the market for shingles alone and with the success of the corporate’s cream on herpes, it might end in NanoViricides catering to a a lot bigger addressable market, estimated to be a number of billions of {dollars}.

Rapidly Improving Finances

One of the largest factors of concern for buyers with respect to improvement stage biotech firms is – what if the corporate is unable to boost adequate funding to finish its analysis and it runs out of money? The NanoViricides administration has dealt with this example splendidly. First and foremost, the corporate has an annualized money burn of hardly $7 million with most of its workers working lengthy shifts in order that the analysis stays uncompromised. Secondly, CEO Anil Diwan himself has dedicated $2 million from his personal cash into the corporate within the type of debt which isn’t solely further pores and skin within the recreation but additionally a adequate quantity to push the corporate for 2020 together with its remaining money reserves. The administration plans to go in for its subsequent spherical of fundraising quickly. Given the low money burn, this is perhaps one of many final rounds of fundraising earlier than NanoViricides begins incomes revenues because the administration is strongly contemplating licensing its program to giant pharmaceutical giants on completion of the Phase I/IIa. This would end in a constant income stream to fund its analysis.

Key Takeaways

While there are a selection of exterior components concerned, it seems to be a matter of hardly eight to 10 weeks earlier than the information on Safety Pharmacology research demonstrating  NanoViricides’ cream to not have any undesirable impact on the bodily techniques. The drug ought to quickly proceed to human trials and this information will definitely act as a giant enhance for the corporate’s stock worth which is presently $2.09 per share with a market capitalization of round $8 million. The Company’s cGMP manufacturing facility itself is an asset price $10 million, after depreciation. The worth of the stock may simply quadruple over 2020 assuming the trials are a hit. The low stage of money burn coupled with the upcoming fundraise will guarantee monetary safety of the corporate and it seems to be a matter of time earlier than they will kickstart their revenues. NanoViricides’ stock is at an inflexion level right this moment and the one route by which it could actually transfer is upwards. It clearly appears to be like like a superb alternative for buyers to purchase and maintain whereas ready for the close to inevitable worth appreciation

DISCLAIMER

Legal Disclaimer

Except for the historic info introduced herein, issues mentioned on this article include forward-looking statements which can be topic to sure dangers and uncertainties that might trigger precise outcomes to vary materially from any future outcomes, efficiency or achievements expressed or implied by such statements. Salesparq, LLC which owns SmallcapsDaily.com isn’t registered with any monetary or securities regulatory authority and doesn’t present nor claims to supply funding recommendation or suggestions to readers of this launch. Salesparq, LLC, which owns SmallcapsDaily.com, could also be compensated for its companies within the type of cash-based compensation for the businesses it writes about. For making particular funding selections, readers ought to search their very own recommendation. Pursuant to an settlement between TraDigital IR and Salesparq, LLC, which owns SmallcapsDaily.com, we have been employed for a interval from 12/15/2019 – 12/31/2019 to publicly disseminate details about NanoViricides Inc., together with on the Website, e mail and different media together with Facebook and Twitter. We have been paid $10,000 (CASH) for & have been paid “0” shares of restricted frequent shares. We personal zero shares of NanoViricides, Inc. We don’t intend to purchase or promote further shares of NanoViricides, Inc. within the open market at any time, together with earlier than, throughout or after the Website and Information, present public dissemination of favorable Information. Please learn our full disclaimer right here: https://smallcapsdaily.com/disclaimer/

Show More

Related Articles

Back to top button
Close

Get Smallcap and Microcap News, Research, Trade Alerts & MORE, all 100% FREE!

Enter your email address to get started. All 100% Free.

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@smallcapsdaily.com